All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View multiple myeloma content recommended for you
The treatment landscape for multiple myeloma (MM) continues to evolve, with B-cell maturation antigen (BCMA)-directed therapies expanding the range of available treatment options. Belantamab mafodotin, a BCMA-directed antibody–drug conjugate (ADC), has been approved in combination regimens for the treatment of relapsed/refractory MM (RRMM) in some regions. Ongoing research continues to explore how to optimize treatment with belantamab mafodotin-based combinations and manage associated toxicities, alongside the potential future role of BCMA-directed ADCs in MM management.
The Multiple Myeloma Hub spoke with Fredrik Schjesvold, Hermann Einsele, and Marc Raab about the clinical use of BCMA-directed ADCs in MM, including the positioning of belantamab mafodotin-based combinations in routine practice, the management of associated ocular toxicities, and future perspectives for BCMA-directed ADCs.
The Multiple Myeloma Hub was pleased to speak to Fredrik Schjesvold, Oslo University Hospital, Oslo, NO. We asked how belantamab mafodotin is currently used in clinical practice for multiple myeloma.
The Multiple Myeloma Hub was pleased to speak to Hermann Einsele, Julius-Maximilians-Universität Würzburg, DE. We asked, How are ocular toxicities associated with belantamab mafodotin managed in MM?
The Multiple Myeloma Hub spoke with Marc Raab, Heidelberg University Hospital, DE. We asked, What is on the horizon for BCMA-directed antibody–drug conjugates in multiple myeloma?
This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
More from this series:
Hermann Einsele
Marc S. Raab
Fredrik Schjesvold
